Solvd Health received FDA approval to use blood samples for its AvertD pharmacogenomic test for opioid use disorder (OUD), extending prior approval that relied on cheek swab collection. The test analyzes 15 genetic variants intended to estimate a patient’s susceptibility to OUD and is positioned as an objective add-on to clinical risk assessment. The company said the blood-based approach is designed to integrate into existing health-system workflows more easily. The test previously drew scrutiny from geneticists and psychiatrists after an FDA approval decision in 2023, and later a case-control study reported weak performance, raising concerns about false positives and negatives. The new approval could broaden adoption if health systems treat genetic risk stratification as actionable—though the debate around evidence quality is likely to continue as more real-world data accumulate.